Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 351 - 400 out of 106,038

Document Document Title
WO/2015/039212A1
Disclosed herein is an agent that modulates a cis interaction between Repulsive Guidance Molecule A (RGMa) and Neogenin or lipid rafts. Modulation by the agent may include blocking the cis interaction between RGMa and Neogenin and/or dis...  
WO/2015/040151A1
The present invention concerns in vivo imaging and in particular in vivo imaging of translocator protein (TSPO, formerly known as the peripheral benzodiazepine receptor). An indole-based in vivo imaging agent is provided that overcomes p...  
WO/2015/037716A1
The present invention provides a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. [In the formula, R1 is an optionally substituted C1-4 alkyl, n is an integer of 1 to 4, R2 is an optionally substituted C...  
WO/2015/036972A2
Working memory deficits are treated and working memory is improved with a composition that comprises a therapeutically effective amount of one or more respective selective dopamine D4 receptor agonists and/or pharmaceutically acceptable ...  
WO/2015/037019A3
The present invention relates to modified release compositions comprising plurality of modified release units. Particularly, the modified release units comprise at least one anti-Alzheimer's agent, at least one ion exchange resin and at ...  
WO/2015/036734A1
The present invention relates a pharmaceutical composition comprising (a) an opioid analgesic drug and/or an enkephalinase inhibitor, and (b) a selective Nav1.7 inhibitor.  
WO/2015/035500A1
Described is the use of L-tryptophan for treating a subject with parasomnia and associated methods of treating a subject with parasomnia. Optionally, the subject may be a child or adolescent between about 3 years of age and 18 years of a...  
WO/2015/036370A1
The present invention relates to a novel use of the active ingredient Pidotimod, or its stereoisomers and/or physiologically acceptable salts thereof, to treat inflammation-associated diseases characterized by an aberrant hyperactivation...  
WO/2015/036412A1
The present invention relates to compounds of general formula (I) wherein R1 is aryl or heteroaryl, which are optionally substituted by one, two or three substituents, selected from lower alkyl, halogen, lower alkyl substituted by haloge...  
WO/2015/035460A1
An antisense oligonucleotide of 10 to 50 nucleotides comprising a targeting sequence complementary to a region near or within intron 6, intron 7, or exon 8 of the Survival Motor Neuron 2 (SMN2) gene pre-mRNA.  
WO/2015/036009A1
The present invention relates to a novel use of the active ingredient Pidotimod, or its stereoisomers and/or physiologicaiiy acceptable salts thereof, to treat inflammation-associated diseases characterized by an aberrant hyperactivation...  
WO/2015/038778A1
This disclosure relates to substituted urea eIF2α kinase activators including methods of making and using the same. For example, such activators can include cycloalkyl aryl ureas, which activate at least one eIF2α kinase. These compoun...  
WO/2015/037248A1
Provided is a novel compound having rapid and long-lasting therapeutic effects on diseases exhibiting depressive symptoms. Specifically, provided are an agent for prevention and/or treatment of a depressive symptom, consisting of R(-)-ke...  
WO/2015/037587A1
This method of producing 4-(((6S,9S)-1-(benzylcarbamoyl)-2,9-dimethyl-4,7-dioxo-8-(qu inoline-8-ylmethyl) octahydro-1H-pyrazino[2,1-c][1,2,4]triazine-6-yl)methyl) phenyl dihydrogen phosphate involves a step for adding a reaction solution...  
WO/2015/036646A1
HSPs (chaperones or heat-shock proteins) possess two very valuable characteristics that can be productively exploited in a specific form in order to "intelligently" manipulate the immune response so as to treat "conformational" disorders...  
WO/2015/038112A1
The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.  
WO/2015/037656A1
 Autophagy-regulating miRNA molecules according to the present invention are formed from base sequences represented by any of SEQ ID NO: 1-203 in the sequence listing. These miRNA molecules were identified using an miRNA screening meth...  
WO/2015/037659A1
 An aqueous solution formulation containing compound (I) can be manufactured by performing the following steps: a first step in which a solution is prepared by dissolving, in an organic solvent, a compound represented by formula (I) or...  
WO/2015/035802A1
The present invention relates to novel vortioxetine salt, a solvate and a crystal form thereof, specifically, vortioxetine hemi-hydrobromide and a crystal form thereof, and a vortioxetine hydrobromide isopropanol solvate and a crystal fo...  
WO/2015/038938A1
Methods and compositions are provided for extending the half-life of a therapeutic agent. One or more half-life extending moieties may be attached to a therapeutic agent, thereby extending the half life of the therapeutic agent. The modi...  
WO/2015/036618A1
The present invention relates to a compound which is an antagonist of the GluK2/GluK5 receptor or an inhibitor of the GluK2/GluK5 receptor expression for use in the treatment or the prevention of epilepsy.  
WO/2015/033267A1
The present invention relates to the diagnostic and therapeutic uses of Arpin, a protein from the Uncharacterized Protein Family UPF0552, which is a new inhibitor of the Arp2/3 that inhibits cell migration and is associated with the prog...  
WO/2015/033175A1
Combination of endogenous pro-opiomelanocortin peptides is combination of the adrenocorticotropic hormone ACTH 1-13 and metenkefalin. The invention is a therapy to substitute corticosteroids, in the disease relapse and at determining the...  
WO/2015/035117A1
Pyrazolo[1,5-a]pyrimidine-based compounds of the formula (I) are disclosed, wherein R1, R2 and R3 are defined herein. Compositions comprising the compounds and methods of their use to treat, manage and/or prevent diseases and disorders m...  
WO/2015/035184A1
Disclosed herein are crystalline forms of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, which is a prodrug of methyl hydrogen fumarate. Crystalline form 1, Crystalline form 2, Crystalline 3, and Crystalline form 4 are dis...  
WO/2015/035414A1
The invention relates to methods for treating neurological disorders by targeting the elimination of selective peripherally activated immune cell populations. The cells may be targeted, for instance, using CLIP inhibitors.  
WO/2015/032328A1
The present invention relates to an indane derivative, a preparation method therefor, and a pharmaceutical application thereof. Specifically, the present invention relates to a compound shown in formula (I), or a stereoisomer thereof, an...  
WO/2015/032233A1
Disclosed in the present invention is the use of a recombinant Lingzhi mushroom immunomodulatory protein (rLZ_8) expressed by Pichia pastoris in the preparation of drugs for treating focal cerebral ischemia. rLZ_8 is able to treat neurol...  
WO/2015/032519A1
Specific mixtures comprising one or more (cannabinoid) compounds of the formula (A) and/or one or more of the salts thereof are described, as are processes for preparation thereof. Also described are a compound of the formula (A), a salt...  
WO/2015/035167A1
Imidazo[1,2-b]pyridazine-based compounds of the formula: are disclosed, wherein R1, R2 and R3 are defined herein. Compositions comprising the compounds and methods of their use to treat, manage and/or prevent diseases and disorders media...  
WO/2015/034012A1
Provided is a method for manufacturing dopamine-producing neural precursor cells from pluripotent stem cells, the method comprising: (i) a step in which pluripotent stem cells are cultured adherently on an extracellular matrix in a cultu...  
WO/2015/032272A1
The present invention relates to a C-aryl glucoside derivative, a preparation method for same, and medical applications thereof. Specifically, the present invention relates to compounds as represented by formula I, and, tautomers, enanti...  
WO/2015/032966A1
The disclosure relates to thecompound2-(cyclohexylmethyl)-N-{2-[(2S)-1- methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline- 7-sulfonamideor a pharmaceutically acceptable salt thereof, intended forthe treatment of Alzheimer's dis...  
WO/2015/035258A1
In some embodiments, the present invention provides certain compositions and methods that may be useful in the treatment and/or prevention of a neurodevelopmental disorder, such as autism or an autism spectrum disorder (ASD). In some suc...  
WO/2015/027949A1
The present invention relates to the application of a deuterated fumaric acid derivative selected from the following group in the preparation of a drug for the treatment or prevention of multiple sclerosis: 2,3-dideuterio- or 2-deuterio-...  
WO/2015/027296A1
The present specification teaches a protocol for pain management including a pharmaceutical composition and its use in ameliorating the sensation of pain. The protocol comprises the use of a CCL17 signaling antagonist alone or in combina...  
WO/2015/029169A1
Provided is Javanese ginger extract wherein the starting material is Javanese ginger and the desired product is a concentrate (containing solid) obtained from a liquid extract. Treatment by heating or exposure to sunlight is performed du...  
WO/2015/027307A1
The present invention describes benzylthiazolidinone derivatives and pharmaceutical compositions comprising the same; these compounds have shown activity in schizophrenia animal models, with the advantage of not causing the typical adver...  
WO/2015/031722A1
The present invention provides use of an inhibitor of G protein-coupled receptor CXCR4 for treating amyotrophic lateral sclerosis (ALS), for inhibiting glutamate release in astrocytes, or for increasing remyelinization in motor neurons.  
WO/2015/027959A1
The present invention relates to a cyclic peptide compound, and a preparation method, pharmaceutical composition and use thereof. In particular, the cyclic peptide compound of the present invention has a structure as shown by general for...  
WO/2015/030628A3
The present invention relates to the field of genetic engineering and medicine. Proposed is a method for treating neurodegenerative diseases and Alzheimer's disease, including the intra-nasal administration to a subject of a therapeut...  
WO/2015/027963A1
The present invention relates to an aromatic ring derivative, and pharmaceutical composition and use thereof, in particular to aromatic ring derivatives or hydrates as represented by general formula (II), solvates, stereoisomers thereof,...  
WO/2015/027518A1
Disclosed is a Chinese herbal medicine health-care cigarette, comprising a cigarette stem and a filter tip connected thereto, wherein shredded tobacco is packed inside the cigarette stem and the shredded tobacco is prepared by mixing 10%...  
WO/2015/029968A1
 Provided is a clock gene expression level modifier having extensive history of use as a food, high safety, ready availability, and exceptional processability. A clock gene expression level modifier having as an active ingredient one o...  
WO/2015/031392A9
The present invention relates to RNA-based methods for inhibiting the expression of the superoxide dismutase 1 (SOD-1) gene. Recombinant adeno-associated viruses of the invention deliver DNAs encoding RNAs that knock down the expression ...  
WO/2015/031493A1
Methods for treating or preventing a seizure in a subject by administering to the subject a therapeutically effective amount of at least one D-amino acid or D-amino acid oxidase inhibitor are provided. In certain aspects, the method redu...  
WO/2015/028409A1
The invention relates to selective estrogen receptor modulators (SERMs) and to methods for the preparation thereof, to the use thereof for the treatment and/or prophylaxis of disorders, and to the use thereof for producing medicaments fo...  
WO/2015/028673A1
The invention concerns the use of a Cav3, especially Cav3.2, channel blocking agent, ethosuximide in particular, in the treatment or prevention of pain triggered by excess nociception, especially of inflammatory origin. The invention als...  
WO/2015/031392A1
The present invention relates to RNA-based methods for inhibiting the expression of the superoxide dismutase 1 (SOD-1) gene. Recombinant adeno-associated viruses of the invention deliver DNAs encoding RNAs that knock down the expression ...  
WO/2015/028848A1
The present invention provides bicyclic heterocyclic compounds (the compounds of formula I, or an isotopic form, a stereoisomer or a tautomer or a pharmaceutically acceptable salt, a solvate, a polymorph, a prodrug or N-oxide thereof and...  

Matches 351 - 400 out of 106,038